|
US10967298B2
(en)
|
2012-03-15 |
2021-04-06 |
Flodesign Sonics, Inc. |
Driver and control for variable impedence load
|
|
US9950282B2
(en)
|
2012-03-15 |
2018-04-24 |
Flodesign Sonics, Inc. |
Electronic configuration and control for acoustic standing wave generation
|
|
US9458450B2
(en)
|
2012-03-15 |
2016-10-04 |
Flodesign Sonics, Inc. |
Acoustophoretic separation technology using multi-dimensional standing waves
|
|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
WO2015105955A1
(en)
|
2014-01-08 |
2015-07-16 |
Flodesign Sonics, Inc. |
Acoustophoresis device with dual acoustophoretic chamber
|
|
CA2945162A1
(en)
|
2014-04-07 |
2015-10-15 |
Minerva Biotechnologies Corporation |
Use of an anti-nme antibody for treatment or prevention of cancer
|
|
CN104004095B
(zh)
*
|
2014-06-04 |
2016-11-23 |
博生吉医药科技(苏州)有限公司 |
一种cd7纳米抗体、其编码序列及应用
|
|
HRP20250129T1
(hr)
|
2014-12-15 |
2025-04-11 |
The Regents Of The University Of California |
Bispecifični or-gate kimerni antigenski receptor koji reagira na cd19 i cd20
|
|
US11021699B2
(en)
|
2015-04-29 |
2021-06-01 |
FioDesign Sonics, Inc. |
Separation using angled acoustic waves
|
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
|
US10434153B1
(en)
|
2015-05-20 |
2019-10-08 |
Kim Leslie O'Neill |
Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
|
|
EP3297672B1
(en)
|
2015-05-21 |
2021-09-01 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
WO2016210293A1
(en)
*
|
2015-06-25 |
2016-12-29 |
Icell Gene Therapeutics Llc |
CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
|
|
US11459540B2
(en)
|
2015-07-28 |
2022-10-04 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
|
US11474085B2
(en)
|
2015-07-28 |
2022-10-18 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
US11236174B2
(en)
|
2016-01-12 |
2022-02-01 |
Crescendo Biologics Limited |
Therapeutic molecules
|
|
CN116063503A
(zh)
|
2016-02-17 |
2023-05-05 |
思进股份有限公司 |
Bcma抗体和其用以治疗癌症和免疫病症的用途
|
|
CN105647946B
(zh)
*
|
2016-03-18 |
2019-09-20 |
江苏普瑞康生物医药科技有限公司 |
一种基于FcγRⅢa的嵌合基因及其用途
|
|
SG11201808411RA
(en)
*
|
2016-04-01 |
2018-10-30 |
Kite Pharma Inc |
Chimeric antigen and t cell receptors and methods of use
|
|
KR102397674B1
(ko)
|
2016-04-01 |
2022-05-18 |
카이트 파마 인코포레이티드 |
Bcma 결합 분자 및 그의 사용 방법
|
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
|
US11085035B2
(en)
|
2016-05-03 |
2021-08-10 |
Flodesign Sonics, Inc. |
Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
|
|
GB201607968D0
(en)
|
2016-05-06 |
2016-06-22 |
Crescendo Biolog Ltd |
Chimeric antigen receptor
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
EP3493844A4
(en)
|
2016-05-20 |
2021-03-24 |
Harpoon Therapeutics Inc. |
SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
|
|
WO2017223111A1
(en)
|
2016-06-21 |
2017-12-28 |
Teneobio, Inc. |
Cd3 binding antibodies
|
|
JP7114490B2
(ja)
*
|
2016-06-24 |
2022-08-08 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
WO2018014039A1
(en)
*
|
2016-07-15 |
2018-01-18 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors (cars) specific for muc1 and methods for their use
|
|
CA3031289A1
(en)
*
|
2016-07-18 |
2018-01-25 |
Helix Biopharma Corp. |
Car immune cells to treat cancer
|
|
HRP20240767T1
(hr)
|
2016-09-14 |
2024-09-13 |
Teneoone, Inc. |
Cd3 vezujuća antitijela
|
|
WO2018058432A1
(zh)
*
|
2016-09-28 |
2018-04-05 |
李华顺 |
一种多基因重组嵌合抗原受体分子及其应用
|
|
WO2018068201A1
(en)
*
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
EP3529347A1
(en)
|
2016-10-19 |
2019-08-28 |
Flodesign Sonics, Inc. |
Affinity cell extraction by acoustics
|
|
CN106755108A
(zh)
*
|
2016-12-05 |
2017-05-31 |
刘晓明 |
一种表达cd19和cd20抗体基因嵌合抗原受体的慢病毒载体及其制备方法
|
|
CN106755109A
(zh)
*
|
2016-12-05 |
2017-05-31 |
刘晓明 |
一种表达人cd19和cd20嵌合抗原受体基因的慢病毒载体
|
|
CN106701827A
(zh)
*
|
2016-12-05 |
2017-05-24 |
刘晓明 |
表达cd19和cd20抗体基因嵌合抗原受体t细胞的转化及扩增培养与保存方法
|
|
ES2926397T3
(es)
|
2016-12-09 |
2022-10-26 |
Onk Therapeutics Ltd |
Células asesinas naturales manipuladas y usos de las mismas
|
|
CN106822184A
(zh)
*
|
2016-12-15 |
2017-06-13 |
梁爱斌 |
多靶点联合的car‑t细胞制剂与制备方法
|
|
NZ754713A
(en)
*
|
2016-12-21 |
2025-11-28 |
Teneobio Inc |
Anti-bcma heavy chain-only antibodies
|
|
CN108276493B
(zh)
*
|
2016-12-30 |
2023-11-14 |
南京传奇生物科技有限公司 |
一种嵌合抗原受体及其应用
|
|
CN106749677B
(zh)
*
|
2017-01-04 |
2020-06-12 |
上海交通大学医学院附属瑞金医院 |
一种靶向mll白血病的双特异性嵌合抗原受体基因及其应用
|
|
EP3565842A1
(en)
|
2017-01-06 |
2019-11-13 |
Crescendo Biologics Limited |
Single domain antibodies to programmed cell death (pd-1)
|
|
EP3577134A1
(en)
|
2017-01-31 |
2019-12-11 |
Novartis AG |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
CN108395482B
(zh)
*
|
2017-02-08 |
2021-02-05 |
西比曼生物科技（香港）有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
|
KR20190116420A
(ko)
|
2017-02-17 |
2019-10-14 |
프레드 헛친슨 켄서 리서치 센터 |
Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
EP3619235A1
(en)
|
2017-04-11 |
2020-03-11 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
CN108728465A
(zh)
*
|
2017-04-14 |
2018-11-02 |
深圳新诺微环生物科技有限公司 |
一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
|
|
AU2018258045B2
(en)
*
|
2017-04-26 |
2024-02-29 |
Eureka Therapeutics, Inc. |
Chimeric antibody/T-cell receptor constructs and uses thereof
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
SG11201910143TA
(en)
|
2017-05-01 |
2019-11-28 |
Juno Therapeutics Inc |
Combination of a cell therapy and an immunomodulatory compound
|
|
EP3622092A4
(en)
|
2017-05-11 |
2021-06-23 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
|
|
IL300964A
(en)
|
2017-05-12 |
2023-04-01 |
Harpoon Therapeutics Inc |
mesothelin binding proteins
|
|
US10415017B2
(en)
|
2017-05-17 |
2019-09-17 |
Thunder Biotech, Inc. |
Transgenic macrophages, chimeric antigen receptors, and associated methods
|
|
EP3624834A1
(en)
*
|
2017-05-17 |
2020-03-25 |
Thunder Biotech Inc. |
Transgenic macrophages, chimeric antigen receptors, and associated methods
|
|
CN107299110B
(zh)
*
|
2017-05-27 |
2019-11-22 |
上海优卡迪生物医药科技有限公司 |
一种基于octs技术的胰腺癌、恶性间皮瘤car-t治疗载体及其构建方法和应用
|
|
CN107245500B
(zh)
*
|
2017-05-27 |
2019-05-17 |
上海优卡迪生物医药科技有限公司 |
一种基于octs技术的淋系白血病car-t治疗载体及其构建方法和应用
|
|
CN107337736B
(zh)
*
|
2017-06-06 |
2019-07-26 |
上海优卡迪生物医药科技有限公司 |
Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用
|
|
US11897953B2
(en)
|
2017-06-14 |
2024-02-13 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
CN117866097A
(zh)
*
|
2017-06-20 |
2024-04-12 |
特尼奥生物股份有限公司 |
仅有重链的抗bcma抗体
|
|
CN117567624A
(zh)
*
|
2017-06-20 |
2024-02-20 |
特纳奥尼股份有限公司 |
仅有重链的抗bcma抗体
|
|
SG10202109108UA
(en)
|
2017-06-21 |
2021-09-29 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars), compositions and methods thereof
|
|
WO2019000223A1
(en)
*
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
SG11201913175TA
(en)
*
|
2017-06-30 |
2020-01-30 |
The United States Of America As Represented By The Secretary |
Anti-b-cell maturation antigen chimeric antigen receptors with human domains
|
|
GB201711068D0
(en)
|
2017-07-10 |
2017-08-23 |
Crescendo Biologics Ltd |
Therapeutic molecules binding PSMA
|
|
CN109232742B
(zh)
*
|
2017-07-11 |
2021-10-22 |
深圳市第二人民医院 |
一种嵌合抗原受体及其应用
|
|
WO2019014581A1
(en)
|
2017-07-14 |
2019-01-17 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
|
|
WO2019014891A1
(zh)
*
|
2017-07-20 |
2019-01-24 |
深圳普瑞金生物药业有限公司 |
一种用于治疗肿瘤的egfr单域抗体cart及其应用
|
|
WO2019018525A1
(en)
*
|
2017-07-20 |
2019-01-24 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
CHIMERIC ANTIGENIC RECEPTORS BINDING TO CD123
|
|
WO2019028051A1
(en)
*
|
2017-07-31 |
2019-02-07 |
Lentigen Technology, Inc. |
COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY
|
|
WO2019046818A1
(en)
*
|
2017-09-01 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER
|
|
CN111133007A
(zh)
*
|
2017-09-13 |
2020-05-08 |
特尼奥生物股份有限公司 |
与胞外酶结合的重链抗体
|
|
US11447559B2
(en)
|
2017-09-29 |
2022-09-20 |
Mogam Institute For Biomedical Research |
Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same
|
|
WO2019070755A1
(en)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
IL315737A
(en)
*
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
CN111630070B
(zh)
*
|
2017-10-13 |
2024-07-30 |
哈普恩治疗公司 |
三特异性蛋白质及使用方法
|
|
TWI829655B
(zh)
|
2017-10-18 |
2024-01-21 |
瑞士商諾華公司 |
用於選擇性蛋白質降解的組合物及方法
|
|
TW201932482A
(zh)
|
2017-11-01 |
2019-08-16 |
美商奇諾治療有限公司 |
對b細胞成熟抗原具特異性之嵌合抗原受體及編碼聚核苷酸
|
|
CN111886012A
(zh)
|
2017-11-06 |
2020-11-03 |
朱诺治疗学股份有限公司 |
细胞疗法与γ分泌酶抑制剂的组合
|
|
AU2018363292A1
(en)
|
2017-11-13 |
2020-05-21 |
Crescendo Biologics Limited |
Molecules that bind to CD137 and PSMA
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
|
AU2018369883A1
(en)
|
2017-11-15 |
2020-05-28 |
Novartis Ag |
BCMA-targeting chimeric antigen receptor, CD19-targeting chimeric antigen receptor, and combination therapies
|
|
RU2020121458A
(ru)
|
2017-11-30 |
2021-12-30 |
Новартис Аг |
Химерный антигенный рецептор, нацеливающийся на bcma, и его пути применения
|
|
KR20220066413A
(ko)
|
2017-12-14 |
2022-05-24 |
프로디자인 소닉스, 인크. |
음향 트랜스듀서 구동기 및 제어기
|
|
US20190192678A1
(en)
*
|
2017-12-18 |
2019-06-27 |
Novather, Inc. |
System and method for the treatment of disease using a hyperspecific modified protein system
|
|
CN118878697A
(zh)
|
2017-12-20 |
2024-11-01 |
波赛达治疗公司 |
Vcar组合物和使用方法
|
|
WO2019126724A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Bluebird Bio, Inc. |
Multivalent chimeric antigen receptor
|
|
CN109970860A
(zh)
*
|
2017-12-27 |
2019-07-05 |
信达生物制药(苏州)有限公司 |
三链抗体、其制备方法及其用途
|
|
CN109971715A
(zh)
*
|
2017-12-28 |
2019-07-05 |
深圳华大生命科学研究院 |
一种扩增特异性car-t细胞的培养方法
|
|
WO2019127215A1
(en)
*
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
|
|
CN109988242A
(zh)
*
|
2018-01-02 |
2019-07-09 |
武汉波睿达生物科技有限公司 |
联合嵌合抗原受体、表达载体、慢病毒及t细胞
|
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
|
CN108285486A
(zh)
*
|
2018-01-15 |
2018-07-17 |
浙江阿思科力生物科技有限公司 |
以cd20为靶点的特异性抗体、car-nk细胞及其制备和应用
|
|
KR102115236B1
(ko)
*
|
2018-01-29 |
2020-05-27 |
(주)에스엠티바이오 |
췌장 또는 담관계암 치료를 위한 키메라 항원 수용체
|
|
CN108341881B
(zh)
*
|
2018-01-31 |
2020-08-18 |
深圳市默赛尔生物医学科技发展有限公司 |
带安全开关的嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
|
|
US20210038659A1
(en)
|
2018-01-31 |
2021-02-11 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
CN108314739B
(zh)
*
|
2018-02-05 |
2020-07-14 |
深圳市默赛尔生物医学科技发展有限公司 |
多信号嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
|
|
CN110129369B
(zh)
*
|
2018-02-09 |
2023-10-13 |
上海交通大学医学院附属上海儿童医学中心 |
一种嵌合抗原受体基因工程载体、免疫细胞及其应用
|
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
GB201802573D0
(en)
|
2018-02-16 |
2018-04-04 |
Crescendo Biologics Ltd |
Therapeutic molecules that bind to LAG3
|
|
WO2019166650A1
(en)
|
2018-03-02 |
2019-09-06 |
Cdr-Life Ag |
Trispecific antigen binding proteins
|
|
CN108220247A
(zh)
*
|
2018-03-20 |
2018-06-29 |
杭州史迪姆生物科技有限公司 |
一种双car-t细胞及其制备方法和应用
|
|
EP3773632A4
(en)
*
|
2018-04-06 |
2022-05-18 |
The Regents of The University of California |
Methods of treating egfrviii expressing glioblastomas
|
|
EP3773633A4
(en)
|
2018-04-06 |
2022-01-26 |
The Regents of The University of California |
METHODS OF TREATMENT OF GLIOBLASTOMA
|
|
EP3549597A1
(en)
*
|
2018-04-06 |
2019-10-09 |
Heinrich-Heine-Universität Düsseldorf |
Synthetic signalling constructs and its use
|
|
SG11202009804RA
(en)
|
2018-04-11 |
2020-11-27 |
Inhibrx Inc |
Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
|
|
CN116836297A
(zh)
*
|
2018-04-12 |
2023-10-03 |
上海赛比曼生物科技有限公司 |
靶向bcma的嵌合抗原受体及其制法和应用
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
MX2020012217A
(es)
|
2018-05-14 |
2021-03-02 |
Harpoon Therapeutics Inc |
Porción de unión para activación condicional de moléculas de inmunoglobulina.
|
|
KR20220080044A
(ko)
*
|
2018-05-16 |
2022-06-14 |
얀센 바이오테크 인코포레이티드 |
암 요법에 사용하기 위한 bcma/cd3 및 gprdc5d/cd3 이중특이성 항체
|
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
CN110606893B
(zh)
*
|
2018-06-15 |
2022-11-15 |
北昊干细胞与再生医学研究院有限公司 |
一种靶向cd19和cd20双抗原的嵌合性抗原受体t细胞治疗肿瘤的方法
|
|
SG11202008731XA
(en)
*
|
2018-06-19 |
2020-10-29 |
Nanjing Legend Biotech Co Ltd |
Engineered cells and uses thereof
|
|
CN112351997B
(zh)
*
|
2018-07-20 |
2023-05-26 |
坦尼奥第二公司 |
与cd19结合的重链抗体
|
|
TW202035451A
(zh)
*
|
2018-07-24 |
2020-10-01 |
美商英伊布里克斯公司 |
含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
|
|
KR20210046006A
(ko)
*
|
2018-08-10 |
2021-04-27 |
상가모 테라퓨틱스 프랑스 |
Tnfr2 도메인을 포함하는 신규한 car 작제물
|
|
GB201813178D0
(en)
*
|
2018-08-13 |
2018-09-26 |
Autolus Ltd |
Cell
|
|
CA3110262C
(en)
*
|
2018-08-24 |
2024-05-14 |
Shenzhen Pregene Biopharma Co. Ltd. |
Anti-bcma single domain antibodies and application thereof
|
|
CN109134665B
(zh)
*
|
2018-08-24 |
2021-06-11 |
上海先博生物科技有限公司 |
一种基于单域抗体的bcma嵌合抗原受体及应用
|
|
AU2019331496A1
(en)
|
2018-08-31 |
2021-03-18 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
CA3111458A1
(en)
|
2018-09-10 |
2020-03-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against cll1 and constructs thereof
|
|
CN109293781A
(zh)
*
|
2018-09-12 |
2019-02-01 |
中国人民解放军总医院 |
嵌合抗原受体及其基因和重组表达载体、cd19-cd20双靶向性的t细胞及其应用
|
|
CN109081870B
(zh)
*
|
2018-09-21 |
2021-12-03 |
成都阿帕克生物科技有限公司 |
一种抗人促绒毛膜促性腺激素β亚单位的纳米抗体及核酸分子和应用
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN109265550B
(zh)
*
|
2018-09-25 |
2020-09-15 |
华东师范大学 |
Bcma抗体、嵌合抗原受体和药物
|
|
IL297931B2
(en)
|
2018-09-25 |
2025-03-01 |
Harpoon Therapeutics Inc |
DLL3 binding proteins and methods of use
|
|
JP2022501067A
(ja)
*
|
2018-09-26 |
2022-01-06 |
上海恒潤達生生物科技有限公司Hrain Biotechnology Co., Ltd. |
Ｂｃｍａ及びｃｄ１９を標的とするキメラ抗原受容体、並びにその使用
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
CN109503716B
(zh)
*
|
2018-10-08 |
2021-04-27 |
浙江生研生物科技有限公司 |
一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用
|
|
CA3115089A1
(en)
*
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
|
CA3100232A1
(en)
*
|
2018-10-26 |
2020-04-30 |
Teneobio, Inc. |
Heavy chain antibodies binding to cd38
|
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
BR112021007626A2
(pt)
|
2018-11-01 |
2021-10-13 |
Juno Therapeutics, Inc. |
Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d)
|
|
CN109504660B
(zh)
*
|
2018-11-02 |
2021-08-06 |
温州启星生物技术有限公司 |
一种第四代car-t细胞及其构建方法和应用
|
|
CN113573719A
(zh)
|
2018-11-08 |
2021-10-29 |
朱诺治疗学股份有限公司 |
治疗和t细胞调节的方法和组合
|
|
CN109468283A
(zh)
*
|
2018-11-30 |
2019-03-15 |
北京美康基免生物科技有限公司 |
一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
CN110951689A
(zh)
*
|
2018-11-30 |
2020-04-03 |
北京美康基免生物科技有限公司 |
一种基于cd19和cd30的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
MX2021006968A
(es)
*
|
2018-12-12 |
2021-10-13 |
Kite Pharma Inc |
Antígeno quimérico y receptores de las células t, y métodos de uso.
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CN109485732B
(zh)
*
|
2018-12-20 |
2021-09-24 |
四川大学华西医院 |
基因工程修饰的双靶点嵌合抗原受体及其用途
|
|
CN109651511B
(zh)
*
|
2018-12-26 |
2020-06-09 |
广州百暨基因科技有限公司 |
一种靶向bcma的嵌合抗原受体及其应用
|
|
US20220144960A1
(en)
*
|
2018-12-26 |
2022-05-12 |
Nanjing Legend Biotech Co., Ltd. |
Cd30-binding moieties, chimeric antigen receptors, and uses thereof
|
|
CN109652379B
(zh)
*
|
2018-12-29 |
2022-08-16 |
博生吉医药科技(苏州)有限公司 |
Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用
|
|
CN109485734B
(zh)
*
|
2018-12-30 |
2020-05-12 |
广州百暨基因科技有限公司 |
一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
JP2022524178A
(ja)
*
|
2019-01-07 |
2022-04-28 |
セルリス パルティシパソエス リミターダ |
タンデム受容体ｃａｒにおける二重特異性と腫瘍マイクロ環境を変調する方法
|
|
CN109678961A
(zh)
*
|
2019-01-15 |
2019-04-26 |
深圳市南科生物工程有限公司 |
一种基于bmca纳米抗体序列的嵌合抗原受体的构建方法及其应用
|
|
WO2020151752A1
(zh)
*
|
2019-01-22 |
2020-07-30 |
亘喜生物科技（上海）有限公司 |
Cd20组合靶向的工程化免疫细胞
|
|
CN113784987B
(zh)
|
2019-01-22 |
2024-09-13 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
|
|
WO2020163325A1
(en)
*
|
2019-02-04 |
2020-08-13 |
Minerva Biotechnologies Corporation |
Anti-nme antibody and method of treating cancer or cancer metastasis
|
|
CN109734814A
(zh)
*
|
2019-02-12 |
2019-05-10 |
南京卡提医学科技有限公司 |
具有免疫受体的工程化t细胞治疗癌症的用途
|
|
US20220152150A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
CN118546959A
(zh)
|
2019-03-05 |
2024-08-27 |
恩卡尔塔公司 |
Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
|
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
CN121102493A
(zh)
|
2019-03-21 |
2025-12-12 |
瑞泽恩制药公司 |
用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
|
|
US20230074800A1
(en)
|
2019-03-21 |
2023-03-09 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
|
MX2021012205A
(es)
|
2019-04-05 |
2022-02-21 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al psma.
|
|
WO2020210678A1
(en)
|
2019-04-12 |
2020-10-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN109942709B
(zh)
*
|
2019-04-22 |
2019-12-27 |
广州百暨基因科技有限公司 |
一种抗bcma的单域抗体及其应用
|
|
JP2022530211A
(ja)
*
|
2019-04-22 |
2022-06-28 |
ナンジン レジェンド バイオテク カンパニー リミテッド |
改変細胞及びその使用
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
EP3733707A1
(en)
|
2019-04-30 |
2020-11-04 |
Celyad S.A. |
Car t-cells targeting bcma and uses thereof
|
|
AU2020265679A1
(en)
|
2019-04-30 |
2021-12-23 |
Senti Biosciences, Inc. |
Chimeric receptors and methods of use thereof
|
|
CN114040927A
(zh)
|
2019-05-04 |
2022-02-11 |
印希比股份有限公司 |
结合cd33的多肽及其用途
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
MX2021014007A
(es)
|
2019-05-14 |
2022-01-24 |
Harpoon Therapeutics Inc |
Proteinas de union a epcam y metodos de uso.
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
EP3980454A4
(en)
*
|
2019-06-04 |
2023-09-20 |
The General Hospital Corporation |
ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETING TACI
|
|
TWI872082B
(zh)
|
2019-06-14 |
2025-02-11 |
美商泰尼歐生物公司 |
與ｃ ｄ ２ ２ 及ｃ ｄ ３ 結合之多特異性重鏈抗體
|
|
EP3990009A1
(en)
*
|
2019-06-27 |
2022-05-04 |
CRISPR Therapeutics AG |
Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
CN110540997B
(zh)
*
|
2019-08-29 |
2024-02-13 |
浙江煦顼技术有限公司 |
靶向bcma嵌合抗原受体、核酸序列、载体及应用
|
|
BR112022003648A2
(pt)
*
|
2019-08-30 |
2022-05-24 |
Janssen Biotech Inc |
Iniciadores e construto de t car complexo de maturação de célula-b
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
WO2021043169A1
(zh)
*
|
2019-09-02 |
2021-03-11 |
成都盛世君联生物技术有限公司 |
特异性结合b细胞成熟抗原的抗体及其用途
|
|
WO2021054789A1
(ko)
*
|
2019-09-18 |
2021-03-25 |
주식회사 에스엘바이젠 |
신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도
|
|
WO2021057866A1
(zh)
*
|
2019-09-26 |
2021-04-01 |
苏州克睿基因生物科技有限公司 |
一种单域抗体及包含抗体结构的嵌合抗原受体
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
WO2021081133A1
(en)
*
|
2019-10-21 |
2021-04-29 |
Purdue Research Foundation |
Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques
|
|
JP7690468B2
(ja)
|
2019-10-22 |
2025-06-10 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
多様な固形腫瘍を処置するためのｂ７ｈ３（ｃｄ２７６）を標的とする高親和性ナノボディ
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
WO2021091945A1
(en)
|
2019-11-05 |
2021-05-14 |
Janssen Biotech, Inc. |
Bcma-targeted car-t cell therapy of multiple myeloma
|
|
CA3163104A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
WO2021105989A1
(en)
*
|
2019-11-26 |
2021-06-03 |
Ramot At Tel-Aviv University Ltd. |
Chimeric antigen receptor to carbohydrate antigens
|
|
WO2021118246A1
(en)
*
|
2019-12-10 |
2021-06-17 |
Abl Bio, Inc. |
Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
|
|
CN115052901B
(zh)
*
|
2019-12-16 |
2025-12-09 |
南京传奇生物科技有限公司 |
靶向bcma的单结构域抗体和嵌合抗原受体及其使用方法
|
|
CN111171158B
(zh)
*
|
2020-01-17 |
2020-10-30 |
南京蓝盾生物科技有限公司 |
同时靶向bcma和cd38的嵌合抗原受体及其应用
|
|
CN111235113A
(zh)
*
|
2020-01-21 |
2020-06-05 |
南京北恒生物科技有限公司 |
包含嵌合抗原受体的免疫细胞及其用途
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
BR112022014667A2
(pt)
|
2020-01-29 |
2022-09-20 |
Inhibrx Inc |
Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
|
|
CN115397973A
(zh)
*
|
2020-01-30 |
2022-11-25 |
免疫生物公司 |
表达car的nk细胞消除bcma阳性恶性肿瘤
|
|
CN111196858B
(zh)
*
|
2020-02-05 |
2021-02-09 |
武汉科技大学 |
一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用
|
|
US20240261329A1
(en)
*
|
2020-02-13 |
2024-08-08 |
Sichuan University |
Chimeric antigen receptor and use thereof
|
|
CN115698285A
(zh)
*
|
2020-02-14 |
2023-02-03 |
小利兰·斯坦福大学董事会 |
具有cd2激活的嵌合抗原受体
|
|
MX2022010604A
(es)
|
2020-02-27 |
2022-09-09 |
Novartis Ag |
Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
|
|
EP4110377A2
(en)
|
2020-02-27 |
2023-01-04 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
JP2023516789A
(ja)
*
|
2020-03-09 |
2023-04-20 |
ヤンセン バイオテツク，インコーポレーテツド |
組換えベクター核酸の統合を定量化するための組成物及び方法
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
CN115916223A
(zh)
|
2020-04-10 |
2023-04-04 |
朱诺治疗学股份有限公司 |
与用靶向b细胞成熟抗原的嵌合抗原受体工程化的细胞疗法相关的方法和用途
|
|
CA3181399A1
(en)
|
2020-04-28 |
2021-11-04 |
Juno Therapeutics, Inc. |
Combination of bcma-directed t cell therapy and an immunomodulatory compound
|
|
CA3176792C
(en)
|
2020-04-29 |
2024-06-18 |
Katherine HARRIS |
Anti-cd3 and anti-bcma bispecific antibodies wth modified heavy chain constant regions
|
|
CN115777017A
(zh)
*
|
2020-05-06 |
2023-03-10 |
亘喜生物科技（上海）有限公司 |
用于t细胞工程改造的组合物及方法
|
|
CN111574629B
(zh)
*
|
2020-06-01 |
2021-07-20 |
宁夏医科大学 |
一种抗cd20的纳米抗体、编码基因、重组纳米抗体、重组载体、重组菌株和应用
|
|
CN111607565A
(zh)
*
|
2020-06-04 |
2020-09-01 |
河南大学 |
一种北平顶猴t细胞的体外扩增方法
|
|
US12049514B2
(en)
|
2020-06-08 |
2024-07-30 |
Minerva Biotechnologies Corporation |
Anti-NME antibody and method of treating cancer or cancer metastasis
|
|
EP4162269A1
(en)
*
|
2020-06-08 |
2023-04-12 |
Janssen Biotech, Inc. |
Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells
|
|
WO2021252920A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
CA3171101A1
(en)
|
2020-06-22 |
2021-12-30 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
|
|
US20230242678A1
(en)
*
|
2020-06-26 |
2023-08-03 |
Minerva Biotechnologies Corporation |
Anti-nme antibody and method of treating cancer or cancer metastasis
|
|
CN114222761B
(zh)
*
|
2020-07-14 |
2024-02-20 |
浙江道尔生物科技有限公司 |
一种抗cld18a2的单域抗体
|
|
AU2021307644A1
(en)
*
|
2020-07-16 |
2023-02-16 |
Legend Biotech Ireland Limited |
CD22 binding molecules and uses thereof
|
|
AU2021308745A1
(en)
*
|
2020-07-16 |
2023-02-16 |
Legend Biotech Ireland Limited |
Multispecific chimeric antigen receptors and uses thereof
|
|
IL299863A
(en)
*
|
2020-07-16 |
2023-03-01 |
Nanjing Legend Biotech Co Ltd |
CD20 binding molecules and uses thereof
|
|
AU2021309145A1
(en)
*
|
2020-07-16 |
2023-02-16 |
Legend Biotech Ireland Limited |
CD19 binding molecules and uses thereof
|
|
CN111848798B
(zh)
*
|
2020-07-27 |
2022-05-13 |
源道隆（苏州）医学科技有限公司 |
可结合bcma的纳米抗体及其应用
|
|
AU2021317073A1
(en)
*
|
2020-07-29 |
2023-02-16 |
National Research Council Of Canada |
Anti-CD22 single domain antibodies and therapeutic constructs
|
|
CN111909271B
(zh)
*
|
2020-08-12 |
2021-03-23 |
深圳市茵冠生物科技有限公司 |
一种基于单域抗体的bcma嵌合抗原受体及其应用
|
|
EP4196504A1
(en)
|
2020-08-13 |
2023-06-21 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Igg4 hinge-containing chimeric antigen receptors targeting glypican-1 (gpc1) for treating solid tumors
|
|
EP4201960A4
(en)
|
2020-08-20 |
2024-09-04 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
BCMA-BINDING SINGLE MOLECULE WITH VARIABLE DOMAIN AND ANTIGEN-BINDING MOLECULE
|
|
EP4202047A4
(en)
|
2020-08-20 |
2024-09-18 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
UNIQUE VARIABLE STRUCTURAL DOMAIN FOR BCMA BINDING AND ANTIGEN BINDING MOLECULE
|
|
WO2022040586A2
(en)
|
2020-08-21 |
2022-02-24 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
CN112062864A
(zh)
*
|
2020-09-18 |
2020-12-11 |
樊克兴 |
靶向bcma肿瘤抗原受体修饰t细胞的制备方法和应用
|
|
CN111925451B
(zh)
*
|
2020-10-12 |
2021-01-29 |
佑仁细胞工程(浙江)有限公司 |
一种靶向bcma的嵌合抗原受体(car)及其应用
|
|
CN112251412B
(zh)
*
|
2020-10-12 |
2023-03-28 |
汤朝阳 |
一种靶向bcma的嵌合抗原受体t细胞及其应用
|
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
CN112028996B
(zh)
*
|
2020-10-30 |
2021-01-22 |
南京北恒生物科技有限公司 |
靶向bcma的单域抗体及其用途
|
|
JP2023549780A
(ja)
|
2020-11-04 |
2023-11-29 |
ジュノー セラピューティクス インコーポレイテッド |
改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
|
|
WO2022116086A1
(en)
*
|
2020-12-03 |
2022-06-09 |
Janssen Biotech, Inc. |
Bcma-targeted car-t cell therapy for multiple myeloma
|
|
WO2022120160A1
(en)
|
2020-12-04 |
2022-06-09 |
Celgene Corporation |
Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
|
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
|
|
TW202237639A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
|
|
CN116917329A
(zh)
*
|
2020-12-17 |
2023-10-20 |
合肥梧桐生物科技有限公司 |
Gucy2c结合分子及其用途
|
|
WO2022143611A1
(zh)
*
|
2020-12-29 |
2022-07-07 |
宁波茂行生物医药科技有限公司 |
靶向bcma的单域抗体
|
|
WO2022140388A1
(en)
|
2020-12-21 |
2022-06-30 |
Allogene Therapeutics, Inc. |
Protease-activating cd45-gate car
|
|
MX2023006207A
(es)
|
2020-12-31 |
2023-08-09 |
Sana Biotechnology Inc |
Métodos y composiciones para modular la actividad de linfocitos t con receptores de antígenos quiméricos (t-car).
|
|
CN112321713B
(zh)
*
|
2020-12-31 |
2021-05-25 |
北京艺妙神州医药科技有限公司 |
一种抗bcma的抗体及其应用
|
|
JP2024503027A
(ja)
|
2021-01-11 |
2024-01-24 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｃｄ８標的ウイルスベクターの使用方法
|
|
CN114149505B
(zh)
*
|
2021-01-12 |
2022-11-04 |
北京门罗生物科技有限公司 |
治疗b细胞相关疾病的免疫细胞、制备方法及其应用
|
|
AU2022214547A1
(en)
*
|
2021-01-27 |
2023-08-17 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Bi-specific car t cells for b cell malignancies
|
|
AU2022212130A1
(en)
|
2021-01-29 |
2023-07-06 |
Allogene Therapeutics, Inc. |
KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
|
|
CN112778427B
(zh)
*
|
2021-01-29 |
2022-03-15 |
武汉思安医疗技术有限公司 |
双特异性cs1-bcma car-t细胞及其应用
|
|
AU2022219373A1
(en)
|
2021-02-15 |
2023-08-24 |
Takeda Pharmaceutical Company Limited |
Cell therapy compositions and methods for modulating tgf-b signaling
|
|
US20240173411A1
(en)
*
|
2021-02-25 |
2024-05-30 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Methods for treating cd83-expressing cancer
|
|
CN117693508A
(zh)
|
2021-03-03 |
2024-03-12 |
朱诺治疗学股份有限公司 |
T细胞疗法和dgk抑制剂的组合
|
|
CN117924496A
(zh)
*
|
2021-03-22 |
2024-04-26 |
浙江纳米抗体技术中心有限公司 |
一种靶向bcma的纳米抗体及其应用
|
|
MX2023011725A
(es)
*
|
2021-04-06 |
2023-10-12 |
Teneobio Inc |
Anticuerpos anti-cd19 y estructuras car-t.
|
|
CN117730091A
(zh)
*
|
2021-04-13 |
2024-03-19 |
悟境股份有限公司 |
改善的嵌合抗原受体及其用途
|
|
WO2022218380A1
(zh)
|
2021-04-15 |
2022-10-20 |
正大天晴药业集团股份有限公司 |
靶向bcma的多特异性抗体
|
|
CA3214683A1
(en)
|
2021-04-16 |
2022-10-20 |
Julie Ann RYTLEWSKI |
Combination therapies with bcma-directed t cell therapy
|
|
PE20240656A1
(es)
*
|
2021-04-16 |
2024-04-04 |
Teneobio Inc |
Anticuerpos anti-cd20 y estructuras car-t
|
|
AU2022257093A1
(en)
|
2021-04-16 |
2023-11-02 |
Celgene Corporation |
T cell therapy in patients who have had prior stem cell transplant
|
|
AR125468A1
(es)
|
2021-04-27 |
2023-07-19 |
Novartis Ag |
Sistema de producción de vectores virales
|
|
US20240218055A1
(en)
|
2021-04-29 |
2024-07-04 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
|
WO2022228579A1
(en)
*
|
2021-04-30 |
2022-11-03 |
Nanjing Legend Biotech Co., Ltd. |
Chimeric antigen receptors targeting gpc3 and methods of use thereof
|
|
JP2024517863A
(ja)
|
2021-05-06 |
2024-04-23 |
ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
細胞を刺激し、形質導入する方法
|
|
TW202309522A
(zh)
|
2021-05-11 |
2023-03-01 |
美商健生生物科技公司 |
用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
|
|
AU2022272021A1
(en)
|
2021-05-11 |
2023-11-30 |
Janssen Biotech, Inc. |
Methods of minimizing neurotoxicity associated with chimeric antigen receptor (car) t cell therapy
|
|
JP2024519869A
(ja)
*
|
2021-05-19 |
2024-05-21 |
セレディット エルエルシー |
二重特異性キメラ抗原受容体、及びそれを発現する遺伝子操作された免疫細胞
|
|
AU2022277931A1
(en)
|
2021-05-19 |
2023-11-30 |
Sana Biotechnology, Inc. |
Hypoimmunogenic rhd negative primary t cells
|
|
MX2023014017A
(es)
|
2021-05-27 |
2023-12-11 |
Sana Biotechnology Inc |
Celulas hipoinmunogenas que comprenden proteina variante del antigeno leucocitario humano e (hla-e) o una proteina variante del antigeno leucocitario humano g (hla-g) modificados geneticamente.
|
|
CN117500831A
(zh)
|
2021-06-09 |
2024-02-02 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体
|
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
AU2022310862A1
(en)
|
2021-07-14 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
|
KR20240046319A
(ko)
|
2021-07-14 |
2024-04-08 |
사나 바이오테크놀로지, 인크. |
저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
|
|
EP4381081A1
(en)
|
2021-08-04 |
2024-06-12 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
|
WO2023019203A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
|
CN113651893B
(zh)
*
|
2021-08-12 |
2023-08-01 |
上海生物制品研究所有限责任公司 |
联合her2和meso双靶点car-t载体及其构建方法和在癌症中的应用
|
|
CA3228773A1
(en)
*
|
2021-08-12 |
2023-02-16 |
Gaurav KHARYA |
Chimeric antigen receptors (car) for b cell malignancies
|
|
EP4388000A1
(en)
|
2021-08-20 |
2024-06-26 |
Novartis AG |
Methods of making chimeric antigen receptor?expressing cells
|
|
US11970548B2
(en)
*
|
2021-08-27 |
2024-04-30 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Nanobody target GCC and uses in chimeric antigen receptor cell therapy
|
|
US11359012B1
(en)
|
2021-08-27 |
2022-06-14 |
Nanjing Kaedi Biotherapeutics Ltd. |
Specific chimeric antigen receptor cells targeting human CLDN18A2, preparation method and application thereof
|
|
CN117586404A
(zh)
*
|
2021-09-24 |
2024-02-23 |
四川大学 |
可特异性靶向人EpCAM抗原的纳米抗体及应用
|
|
IL311765A
(en)
*
|
2021-09-29 |
2024-05-01 |
Modex Therapeutics Inc |
Antigen-binding polypeptides, antigen-binding polypeptide complexes and methods of using them
|
|
US20250000976A1
(en)
*
|
2021-10-07 |
2025-01-02 |
National Research Council Of Canada |
Anti-bcma single domain antibodies and therapeutic constructs
|
|
US20250313861A1
(en)
|
2021-10-22 |
2025-10-09 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
|
WO2023076881A1
(en)
|
2021-10-26 |
2023-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
|
|
CN114015674B
(zh)
|
2021-11-02 |
2024-08-30 |
辉大(上海)生物科技有限公司 |
一种CRISPR-Cas12i系统
|
|
JP2024540320A
(ja)
|
2021-11-03 |
2024-10-31 |
セルジーン コーポレーション |
骨髄腫を処置する際に使用するための、ｂ細胞成熟抗原に特異的なキメラ抗原受容体
|
|
JP2024540304A
(ja)
|
2021-11-03 |
2024-10-31 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｃｄ３８抗体による治療におけるコルチコステロイドの減少
|
|
WO2023077343A1
(en)
|
2021-11-04 |
2023-05-11 |
Janssen Biotech, Inc. |
Bcma-targeted car-t cell therapy for multiple myeloma
|
|
IL312602A
(en)
|
2021-11-04 |
2024-07-01 |
Janssen Biotech Inc |
Bcma-targeted car-t cell therapy for multiple myeloma
|
|
EP4429767A1
(en)
|
2021-11-09 |
2024-09-18 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Igg4 hinge-containing chimeric antigen receptors targeting glypican-3 (gpc3) and use thereof
|
|
CN115466331B
(zh)
*
|
2021-11-18 |
2023-05-30 |
合源生物科技(天津)有限公司 |
靶向bcma的嵌合抗原受体及其应用
|
|
JP2025501461A
(ja)
*
|
2021-12-07 |
2025-01-22 |
イノベント バイオロジクス（スーチョウ）カンパニー，リミティド |
Ｂｃｍａに結合する抗体およびその使用
|
|
CN114195898B
(zh)
*
|
2021-12-13 |
2022-10-28 |
南京凯地医疗技术有限公司 |
人源化抗cd33的单域抗体及其构建体制备方法和应用
|
|
CN118401561A
(zh)
*
|
2021-12-16 |
2024-07-26 |
浙江瑞加美生物科技有限公司 |
人源化的bcma抗体和bcma-car-t/bcma-car-dnt细胞
|
|
EP4448775A1
(en)
|
2021-12-17 |
2024-10-23 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
WO2023115039A2
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
KR20240137574A
(ko)
|
2021-12-23 |
2024-09-20 |
사나 바이오테크놀로지, 인크. |
자가면역 질환 치료를 위한 키메라 항원 수용체[chimeric antigen receptor, car] t 세포 및 관련 방법
|
|
JP2025508298A
(ja)
*
|
2021-12-29 |
2025-03-26 |
ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー |
シングルドメイン高親和性抗体及びその使用方法
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
JP2025504002A
(ja)
|
2022-01-28 |
2025-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
細胞組成物を製造する方法
|
|
US20250152709A1
(en)
|
2022-02-01 |
2025-05-15 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
EP4473097A1
(en)
|
2022-02-02 |
2024-12-11 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
AU2023221836A1
(en)
|
2022-02-15 |
2024-08-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cd28 hinge and transmembrane containing chimeric antigen receptors targeting gpc2 and use thereof
|
|
IL315000A
(en)
|
2022-02-17 |
2024-10-01 |
Sana Biotechnology Inc |
Engineered cd47 proteins and uses thereof
|
|
AU2023223523A1
(en)
|
2022-02-28 |
2024-09-26 |
Janssen Biotech, Inc. |
Bcma-targeted car-t cell therapy for multiple myeloma
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
JP2025511872A
(ja)
|
2022-04-08 |
2025-04-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
多部位受容体及びシグナル伝達複合体
|
|
CN114685664B
(zh)
*
|
2022-04-12 |
2023-10-20 |
内蒙古农业大学 |
抗人b淋巴细胞表面抗原cd20的单域抗体及其应用
|
|
US20250297282A1
(en)
|
2022-05-05 |
2025-09-25 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
CN119212724A
(zh)
*
|
2022-05-09 |
2024-12-27 |
上海先博生物科技有限公司 |
工程化免疫效应细胞及其与CBL-b抑制剂联用的应用
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
EP4522183A2
(en)
|
2022-05-11 |
2025-03-19 |
Celgene Corporation |
Methods and uses related to t cell therapy and production of same
|
|
EP4532695A1
(en)
|
2022-05-25 |
2025-04-09 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
AU2023276514A1
(en)
*
|
2022-05-27 |
2024-12-05 |
Suzhou Immunofoco Biotechnology Co., Ltd |
Chimeric antigen receptor containing cldn18.2 single domain antibody and application thereof
|
|
EP4536710A1
(en)
*
|
2022-06-13 |
2025-04-16 |
The Regents of the University of California |
Humanized antibodies to human integrin avb8
|
|
US12297285B2
(en)
*
|
2022-06-24 |
2025-05-13 |
Orna Therapeutics, Inc. |
Circular RNA encoding chimeric antigen receptors targeting BCMA
|
|
CN114805582B
(zh)
*
|
2022-06-29 |
2022-10-04 |
上海恒润达生生物科技股份有限公司 |
抗Trop2纳米抗体及其用途
|
|
CA3259982A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
CA3261440A1
(en)
|
2022-07-29 |
2024-02-01 |
Allogene Therapeutics, Inc. |
MODIFIED CELLS WITH REDUCED GENE EXPRESSION TO MITIGATE RECOGNITION BY IMMUNE CELLS
|
|
WO2024026455A2
(en)
*
|
2022-07-29 |
2024-02-01 |
Shoreline Biosciences, Inc. |
Methods and compositions for generating chimeric antigen receptor-monocytes/macrophages
|
|
KR20250047766A
(ko)
|
2022-08-05 |
2025-04-04 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Gprc5d 및 bcma에 특이적인 키메라 항원 수용체
|
|
WO2024041650A1
(en)
*
|
2022-08-25 |
2024-02-29 |
Nanjing Legend Biotech Co., Ltd. |
Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof
|
|
WO2024050399A1
(en)
|
2022-09-01 |
2024-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
|
|
CN116023495B
(zh)
*
|
2022-09-05 |
2023-10-03 |
上海百英生物科技股份有限公司 |
一种抗cd40纳米抗体及其制备方法与应用
|
|
CN120152717A
(zh)
|
2022-09-08 |
2025-06-13 |
朱诺治疗学股份有限公司 |
T细胞疗法和连续或间歇dgk抑制剂给药的组合
|
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
CN115925947B
(zh)
*
|
2022-09-27 |
2023-08-22 |
上海百英生物科技股份有限公司 |
一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
EP4602174A1
(en)
|
2022-10-13 |
2025-08-20 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
WO2024089639A1
(en)
|
2022-10-26 |
2024-05-02 |
Novartis Ag |
Lentiviral formulations
|
|
CN117384299B
(zh)
*
|
2022-11-01 |
2024-04-30 |
邦恩泰(山东)生物医药科技集团股份有限公司 |
靶向bcma和/或fcrh5的嵌合抗原受体、car-t细胞及其应用
|
|
EP4611798A1
(en)
|
2022-11-02 |
2025-09-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
US20240156962A1
(en)
*
|
2022-11-02 |
2024-05-16 |
Legend Biotech Usa Inc. |
Bcma-targeted car-t cell therapy of multiple myeloma
|
|
JP2025537156A
(ja)
*
|
2022-11-04 |
2025-11-14 |
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド |
Ｂｃｍａ ｖｈのみのｃａｒ
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
EP4630043A1
(en)
|
2022-12-06 |
2025-10-15 |
Dynamic Cell Therapies, Inc. |
Immune-activating complexes
|
|
CN117069844B
(zh)
*
|
2022-12-06 |
2024-02-09 |
成都赛恩吉诺生物科技有限公司 |
包含特定等电点的抗人bcma纳米抗体的双特异性抗体及应用
|
|
WO2024123835A1
(en)
|
2022-12-06 |
2024-06-13 |
Dynamic Cell Therapies, Inc. |
Engineered switches for immune cell activity and methods of use thereof
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
WO2024124132A1
(en)
|
2022-12-09 |
2024-06-13 |
Juno Therapeutics, Inc. |
Machine learning methods for predicting cell phenotype using holographic imaging
|
|
KR20240094169A
(ko)
*
|
2022-12-13 |
2024-06-25 |
진셀비티 주식회사 |
B-세포 성숙 항원을 표적화하는 신규한 키메라 항원 수용체 및 이의 용도
|
|
CN115947853B
(zh)
*
|
2022-12-26 |
2024-06-28 |
河北森朗生物科技有限公司 |
靶向bcma的纳米抗体、嵌合抗原受体及其应用
|
|
AU2024214593A1
(en)
|
2023-02-03 |
2025-08-07 |
C3S2 Gmbh |
Methods for non-viral manufacturing of engineered immune cells
|
|
WO2024168192A1
(en)
|
2023-02-10 |
2024-08-15 |
Celgene Corporation |
Assessment of bcma in biological samples
|
|
CN120098126A
(zh)
*
|
2023-02-22 |
2025-06-06 |
成都优赛诺生物科技有限公司 |
一种靶向cd22的单域抗体、嵌合抗原受体及其应用
|
|
US20240350630A1
(en)
|
2023-02-22 |
2024-10-24 |
Astrazeneca Ab |
Compositions and methods of treating disease with chimeric antigen receptors to b cell maturation antigen (bcma)
|
|
WO2024206209A1
(en)
*
|
2023-03-27 |
2024-10-03 |
Modernatx, Inc. |
Anti-cd38, anti-bcma, anti-gprc5d, and anti-fcrh5 antibodies and uses to treat various diseases such as cancer
|
|
EP4626447A1
(en)
|
2023-03-31 |
2025-10-08 |
AbelZeta Inc. |
Bispecific chimeric antigen receptors targeting cd20 and bcma
|
|
CN116640229B
(zh)
*
|
2023-04-10 |
2024-01-30 |
中国人民解放军总医院第五医学中心 |
一种低pH靶向性CAR-T细胞的构建及应用
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
WO2024220574A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
CA3205511A1
(en)
*
|
2023-04-19 |
2025-03-17 |
Janssen Biotech, Inc. |
Bcma-targeted car-t cell therapy for multiple myeloma
|
|
WO2024238346A1
(en)
|
2023-05-12 |
2024-11-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
|
|
WO2024243340A1
(en)
|
2023-05-23 |
2024-11-28 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
WO2024240248A1
(zh)
*
|
2023-05-24 |
2024-11-28 |
茂行制药(苏州)有限公司 |
用于靶向b7h3的同种异体嵌合抗原受体t细胞的给药的方法和组合物
|
|
CN117986387A
(zh)
*
|
2023-05-31 |
2024-05-07 |
四川大学华西医院 |
一种新型小型化car设计及制备方法和应用
|
|
WO2024249954A1
(en)
|
2023-05-31 |
2024-12-05 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
CN116789859B
(zh)
*
|
2023-06-29 |
2024-02-23 |
徐州医科大学 |
一种用于评价bcma靶向car-t细胞药效的靶细胞及其应用
|
|
CN116949099B
(zh)
*
|
2023-07-12 |
2024-04-02 |
山东大学第二医院 |
一种靶向cd38和cs1抗原的并联嵌合抗原受体t细胞及其制备方法和应用
|
|
WO2025019228A1
(en)
|
2023-07-20 |
2025-01-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
|
|
WO2025029930A1
(en)
|
2023-07-31 |
2025-02-06 |
Legend Biotech Ireland Limited |
Cells overexpressing cd31 and methods of use thereof
|
|
WO2025043172A1
(en)
|
2023-08-23 |
2025-02-27 |
Sana Biotechnology, Inc. |
Modified cd47 proteins and their uses
|
|
GR1010884B
(el)
*
|
2023-08-30 |
2025-02-19 |
Janssen Biotech, Inc., |
Θεραπεια τ κυτταρων με χιμαιρικο υποδοχεα αντιγονου (car) με στοχευμενο αντιγονο ωριμανσης των β κυτταρων (bcma) για πολλαπλο μυελωμα
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
CN117024594B
(zh)
*
|
2023-09-21 |
2025-02-28 |
武汉波睿达生物科技有限公司 |
一种抗cd20的纳米抗体及其应用
|
|
WO2025067472A1
(en)
*
|
2023-09-27 |
2025-04-03 |
Nanjing Legend Biotech Co., Ltd. |
Methods of culturing gamma delta t cells
|
|
AR134056A1
(es)
|
2023-10-05 |
2025-11-26 |
Janssen Biotech Inc |
Métodos mejorados en la fabricación de lentivirales para la producción de productos farmacéuticos de células car-t
|
|
WO2025076127A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
WO2025096560A1
(en)
|
2023-10-30 |
2025-05-08 |
Allogene Therapeutics, Inc. |
Engineered cells
|
|
US20250144234A1
(en)
|
2023-11-02 |
2025-05-08 |
Capstan Therapeutics Inc. |
RNA for In vivo Transfection with Increased Expression
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
GB202317065D0
(en)
|
2023-11-07 |
2023-12-20 |
Coding Bio Ltd |
BCMA binding molecules
|
|
WO2025098446A1
(zh)
*
|
2023-11-07 |
2025-05-15 |
赛斯尔擎生物技术（上海）有限公司 |
抗bcma单域抗体及其应用
|
|
CN120025440A
(zh)
*
|
2023-11-21 |
2025-05-23 |
南京融捷康生物科技有限公司 |
一种抗Nkp46的单域抗体及其用途
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025129201A1
(en)
|
2023-12-15 |
2025-06-19 |
Capstan Therapeutics, Inc. |
Humanized anti-cd8 antibodies and uses thereof
|
|
WO2025130984A1
(en)
*
|
2023-12-20 |
2025-06-26 |
Overland Therapeutics (Us) Inc. |
Single domain antibodies for bcma
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
KR102869233B1
(ko)
*
|
2024-01-24 |
2025-10-15 |
주식회사 박셀바이오 |
Bcma 특이적 키메라 항원 수용체를 포함하는 신규한 골수 침윤 림프구 집단 및 이의 제조방법
|
|
WO2025160340A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
TW202540428A
(zh)
|
2024-01-26 |
2025-10-16 |
美商雷傑納榮製藥公司 |
使用漿細胞耗乏劑及／或ｂ細胞耗乏劑遏制宿主抗ａａｖ抗體反應且實現ａａｖ轉導及重複給藥的方法及組成物
|
|
WO2025170902A1
(en)
|
2024-02-05 |
2025-08-14 |
Legend Biotech Usa Inc. |
Bcma-targeted car-t cell therapy for multiple myeloma
|
|
WO2025171383A2
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens and related methods and uses
|
|
WO2025171388A1
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens with modified domains and related methods and uses
|
|
WO2025179294A2
(en)
|
2024-02-22 |
2025-08-28 |
Capstan Therapeutics, Inc. |
Immune engineering amplification
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
CN117866904B
(zh)
*
|
2024-03-12 |
2024-06-07 |
北京贝来药业有限公司 |
基于单域抗体基因修饰的干细胞对于多种的疾病的制药用途
|
|
CN117866903B
(zh)
*
|
2024-03-12 |
2024-06-04 |
北京贝来药业有限公司 |
单域抗体修饰的干细胞及其在疾病治疗中用途
|
|
WO2025193685A1
(en)
|
2024-03-12 |
2025-09-18 |
Legend Biotech Usa Inc. |
Bcma-targeted car-t cell therapy for multiple myeloma
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025221781A2
(en)
|
2024-04-15 |
2025-10-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting fgfr4 and/or cd276 and use thereof for the treatment of cancer
|
|
WO2025231408A2
(en)
|
2024-05-03 |
2025-11-06 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma with car-t cells and bispecific antibodies
|
|
WO2025231372A2
(en)
|
2024-05-03 |
2025-11-06 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma with car-t cells and bispecific antibodies
|
|
WO2025232812A1
(en)
*
|
2024-05-08 |
2025-11-13 |
Shanghai Vitalgen Biopharma Co., Ltd. |
Biomolecule conjugated lipid nanoparticles
|
|
WO2025235598A1
(en)
|
2024-05-09 |
2025-11-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting glypican-2 and/or cd276 and their use for treating solid tumors
|
|
WO2025240496A1
(en)
|
2024-05-14 |
2025-11-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Natural killer cells expressing a mesothelin-targeted chimeric antigen receptor and interleukin-15 for the treatment of solid tumors
|
|
WO2025255266A1
(en)
|
2024-06-05 |
2025-12-11 |
Dynamic Cell Therapies, Inc. |
Engineered polypeptides for immune cell activation
|
|
WO2026006767A1
(en)
|
2024-06-28 |
2026-01-02 |
Dispatch Biotherapeutics, Inc. |
Tethered il-9/il-9r and related engineered cells and methods
|
|
CN120173114B
(zh)
*
|
2025-03-24 |
2025-09-26 |
广州泽朗生物医药科技有限公司 |
Cart细胞及其在制备抗癌症药物中的应用
|